Analytical Data
-
Gene name
NGAL
- Application
-
Alternative Names
Lipocalin-2; LCN2; p25; Lipocalin 2; Oncogene 24p3; 25 kDa alpha-2-microglobulin-related subunit of MMP-9; Siderocalin LCN2
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30152
-
Expression Region
Gln21~Asn198
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small, secreted protein that plays a significant role in various physiological and pathological processes, particularly in the context of acute kidney injury (AKI) and inflammation. As a component of the lipocalin family, NGAL binds to small hydrophobic molecules and is involved in the transport of these molecules, which contributes to its diverse biological functions. Elevated levels of NGAL in urine and serum have been identified as promising early biomarkers for AKI, facilitating early diagnosis and intervention. Research into recombinant NGAL (rNGAL) focuses on its potential therapeutic applications, as well as its mechanistic role in kidney protection and repair. The production of rNGAL using recombinant DNA technology allows for the study of its structure, function, and interaction with other proteins, making it a valuable tool for investigating renal pathology. Moreover, the potential use of rNGAL as a biomarker or therapeutic agent has spurred interest in understanding its modulatory effects on inflammation and fibrosis within the kidneys. By delineating the role of NGAL in renal physiology and disease, researchers aim to develop targeted strategies for preventing or treating AKI and improving patient outcomes.
